Polymyalgia rheumatica

Area of Science:

• Rheumatology
• Immunology
• Internal Medicine

Background:

• Polymyalgia rheumatica (PMR) is an inflammatory condition affecting individuals over 50, causing shoulder and pelvic girdle pain and stiffness.
• Diagnosis relies on excluding other conditions due to a lack of specific tests, with imaging aiding in pathological identification and detecting coexistent giant cell arteritis.
• PMR significantly impacts quality of life, though it doesn't typically affect survival or organ function.

Purpose of the Study:

• To review the current understanding of polymyalgia rheumatica, including diagnosis, management, and emerging therapies.
• To highlight the challenges in assessing disease activity and managing relapses and side-effects associated with glucocorticoid treatment.
• To discuss the potential of newer targeted therapies in improving patient outcomes.

Main Methods:

• Review of existing literature on polymyalgia rheumatica, focusing on diagnostic criteria, treatment outcomes, and novel therapeutic agents.
• Analysis of the role of imaging in diagnosis and disease activity assessment.
• Evaluation of the efficacy and safety of current and emerging treatments, including glucocorticoids and biologics.

Main Results:

• Glucocorticoids are effective for remission but associated with high relapse rates (40-60%) and common side-effects upon tapering.
• Assessing disease activity is challenging due to comorbidities and altered inflammatory marker responses during treatment.
• Tocilizumab and sarilumab have demonstrated efficacy in clinical trials, indicating promise for targeted therapies.

Conclusions:

• Polymyalgia rheumatica requires careful management due to treatment challenges and quality of life impacts.
• Emerging targeted therapies, such as IL-6 inhibitors, show promise for more effective and potentially safer treatment strategies.
• A careful risk-benefit assessment is crucial when implementing new therapeutic innovations for polymyalgia rheumatica patients.